Lifastuzumab vedotin对比聚乙二醇脂质体多柔比星治疗铂耐药卵巢癌的随机II期研究
该随机开放标签II期研究纳入95例铂耐药卵巢癌患者,比较抗NaPi2b抗体偶联药物LIFA(2.4 mg/kg Q3W)与PLD(40 mg/m2 Q4W)。LIFA组客观缓解率显著优于PLD组(ITT人群34% vs 15%,P=0.03),但PFS改善未达统计学显著(中位5.3 vs 3.1个月,HR=0.78,P=0.34)。LIFA耐受性良好,≥3级不良事件发生率与PLD相近。
要点
- LIFA在铂耐药卵巢癌中客观缓解率显著优于PLD(34% vs 15%,P=0.03)。
- LIFA的PFS改善未达统计学显著(中位5.3 vs 3.1个月,HR=0.78,P=0.34)。
- LIFA耐受性良好,≥3级不良事件发生率与PLD相近(46% vs 51%)。
核心结论
- LIFA Q3W耐受性良好,相比PLD提高了铂耐药卵巢癌的客观缓解率,PFS改善温和但未达统计学显著。
研究设计与样本
- 随机、开放标签II期研究,纳入95例铂耐药卵巢癌患者,随机接受LIFA(47例)或PLD(48例)。
主要发现
- ITT人群 stratified PFS HR为0.78(95%CI 0.46-1.31,P=0.34),中位PFS LIFA组5.3个月 vs PLD组3.1个月。
- NaPi2b高表达人群PFS HR为0.71(95%CI 0.40-1.26,P=0.24),中位PFS 5.3 vs 3.4个月。
- ITT人群客观缓解率LIFA组34%(95%CI 22%-49%)vs PLD组15%(95%CI 7%-28%),P=0.03。
- NaPi2b高表达人群客观缓解率LIFA组36%(95%CI 22%-52%)vs PLD组14%(95%CI 6%-27%),P=0.02。
- ≥3级不良事件发生率LIFA组46%、PLD组51%;严重不良事件两组均为30%;导致停药的不良事件LIFA组9%、PLD组8%。
关键数值与推荐
- LIFA剂量为2.4 mg/kg静脉注射每3周一次;PLD剂量为40 mg/m2静脉注射每4周一次。
临床怎么用
- LIFA在铂耐药卵巢癌中显示较高的客观缓解率,但缓解持续时间相对较短,提示评估ADC时需同时关注缓解率和缓解持续时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lifastuzumab vedotin (LIFA) is a humanized anti-NaPi2b monoclonal antibody conjugated to a potent antimitotic agent, monomethyl auristatin E, which inhibits cell division by blocking the polymerization of tubulin. This study is the first to compare an antibody-drug conjugate (ADC) to standard-of-care in ovarian cancer (OC) patients. PATIENTS AND METHODS: Platinum-resistant OC patients were randomized to receive LIFA [2.4 mg/kg, intravenously, every 3 weeks (Q3W)] or pegylated liposomal doxorubicin (PLD) (40 mg/m2, intravenously, Q4W). NaPi2b expression and serum CA-125 and HE4 levels were assessed. The primary end point was progression-free survival (PFS) in intent-to-treat (ITT) and NaPi2b-high patients. RESULTS: Ninety-five patients were randomized (47 LIFA; 48 PLD). The stratified PFS hazard ratio was 0.78 [95% confidence interval (95% CI), 0.46-1.31; P = 0.34] with a median PFS of 5.3 versus 3.1 months (LIFA versus PLD arm, respectively) in the ITT population, and 0.71 (95% CI, 0.40-1.26; P = 0.24) with a median PFS of 5.3 months versus 3.4 months (LIFA versus PLD arm, respectively) in NaPi2b-high patients. The objective response rate was 34% (95% CI, 22% to 49%, LIFA) versus 15% (95% CI, 7% to 28%, PLD) in the ITT population (P = 0.03), and 36% (95% CI, 22% to 52%, LIFA) versus 14% (95% CI, 6% to 27%, PLD) in NaPi2b-high patients (P = 0.02). Toxicities included grade ≥3 adverse events (AEs) (46% LIFA; 51% PLD), serious AEs (30% both arms), and AEs leading to discontinuation of drug (9% LIFA; 8% PLD). Five (11%) LIFA versus 2 (4%) PLD patients had grade ≥2 neuropathy. CONCLUSION: LIFA Q3W was well tolerated and improved objective response rate with a modest, nonstatistically significant improvement of PFS compared with PLD in platinum-resistant OC. While the response rate for the monomethyl auristatin E-containing ADC was promising, response durations were relatively short, thereby highlighting the importance of evaluating both response rates and duration of response when evaluating ADCs in OC. CLINICAL TRIALS.GOV: NCT01991210.
引用
- Banerjee S, Oza AM, Birrer MJ, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018. PMID: 29401246. doi:10.1093/annonc/mdy023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。